Showing 4 results for Liver Enzyme
Nikdokht Taghavi, Hassan Afzali, Hamid Sohrabpour,
Volume 17, Issue 4 (2-2004)
Abstract
Tuberculosis is one of the oldest diseases that affects humans. The cause of this
disease is Mycobacterium tuberculosis. This disease affects approximately 8.8 million
people worldwide and led to over 3 million deaths in 1995.
95% of those affected and 98% of deaths occurred in developing countries. Hepatic
reactions constitute a major proportion of drug reactions to antituberculosis drugs
being reported in 4% of cases treated with rifampin/isoniazid and pyrazinamide in the
US A and 8-50% in India and developing countries.
For the purpose of identifying the hepatotoxicity of anti-tuberculous drugs, this
study was performed in hospitals affiliated to Shahid Beheshti University in Tehran
during 1994 to 1997.
The current descriptive study was performed on hospitalized patients diagnosed
as having active tuberculosis.
History was taken from all the patients and clinical signs were recorded. Three
sputum samples for mycobacterial acid fast stain examination and cultures (three consecutive
days) were sent to Pasteur Institute. Liver function tests (AST, ALT, alkaline
phosphatase, bilirubin, PT) were performed before treatment and repeated weekly for
two weeks then two weekly for the first two months and then monthly until the end of
treatment.
From a total of 262 patients during the study, 190 patients were studied. 51 %
were male and the rest were female.
The lowest rate of TB was in the age group less than 5 and the most frequent rate
ofTB was in the 56-65 years age group. 107 patients (56.2%) had active pulmonary
tuberculosis and 43.7% had extra-pulmonary TB. 44.2% had positive smear sputum,
22.1 % had positive biopsy, and 33.6% were diagnosed based on clinical findings, xrays
and other paraclinical tests. 25.7% of patients had increased ALT and AST following
the treatment, and in 4.7% of cases the increase was 4-5 times normal and in
3.6% 5 times normal, 8.4% had increase in bilirubin and 6.8% had increase in bilirubin
associated with increase in ALT and AST, 8.4% had increased alkaline phosphatase
and 7.6% had disturbance in PT.
Considering that 25.7% of the patients had increased levels of liver enzymes and
in 3.6% of them the increased level exceeded 5 times that of normal and also 6 cases of
7 were over 35 years old, therefore, anti-tuberculosis drug consumption, must be considered
more seriously in patients over the age of 35.
Fereshteh Baygi, Olaf C Jensen, Mostafa Qorbani, Aliasghar Farshad, Seyed Ali Salehi, Fatemeh Mohammadi, Hamid Asayesh, Farzad Shidfar,
Volume 31, Issue 1 (1-2017)
Abstract
Background: Little information is available on the trend in cardiovascular risk factors and hepatic enzymes in Iranian seafarers. The present study aimed to assess the pattern of obesity, hypertension, diabetes, elevated serum glutamic oxaloacetate transaminase (SGOT), and serum glutamate pyruvate transaminase (SGPT) in Iranian seafarers during 2010 to 2014.
Methods: Data on cardiovascular risk factors and hepatic enzymes were extracted from seafarers’ annual health examination of National Iranian Tanker Company (NITC) of 2010, 2012, and 2014. Over weight was defined as BMI (Body Mass Index) >25 kg/m2; obesity was defined as BMI>=30 kg/m2; hypertension was defined as systolic blood pressure (SBP)> 140 mmHg and diastolic blood pressure (DBP)> 90 mmHg or a history of antihypertensive drug use; diabetes (DM) was defined as fasting blood sugar (FBS) > 110 mg/dl or having a history of oral hypoglycemic agents; elevated SGOT and SGPT were defined as SGOT > 40 U/L and SGPT > 40 U/L, respectively.
Results: The BMI mean values of Iranian seafarers were 24.81±3.07 kg/m2, 25.51±2.96 kg/m2, and 25.96 ± 3.02 kg/m2 in 2010, 2012, and 2014, respectively. A significant difference was observed in BMI over the study period. The mean of systolic and diastolic blood pressure did not significantly increase over the time. The SGOT and SGPT means were not significantly different from 2010 to 2014. The prevalence of over weight increased significantly from 46.7% to 60.9% over the study period, and the prevalence of obesity, hypertension, elevated SGOT, and elevated SGPT did not change significantly.
Conclusion: The current survey showed that the obesity problem has increased among Iranian seafarers working on tankers, which is a concerning problem since obesity has negative effect on seafarers’ health.
Lida Nejati, Ariyo Movahedi, Gholam Reza Salari, Reza Moeineddin, Parisa Nejati,
Volume 36, Issue 1 (1-2022)
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver disorders with a relatively high mortality rate. Berberine has recently been found to have some antidiabetic and antihyperlipidemic effects, although the evidence of its effectiveness in NAFLD is limited. To assess the efficacy of berberine among patients with NAFLD.
Methods: The patients with NAFLD were randomly assigned to treatment with (n = 25) or without (n = 25) berberine. The patients in the intervention group took berberine 6.25 g per day and the control group had no berberine. All patients in the 2 groups had been recommended to have lifestyle training, including a low-fat diet and physical activity before randomization. Independent student t tests or Mann-Whitney U tests along paired t tests or Wilcoxon signed-rank tests were used. Analysis of covariance was also used to estimate the difference of the variables between the 2 groups adjusting for baseline characteristics.
Results: The results indicated that berberine, compared with the control group, had no significant impact on lipid levels, including triglyceride (P = 0.350), total cholesterol (P = 0.120), high-density lipoproteins (P = 0.401), and low-density lipoproteins (P = 0.100). Similarly, no significant difference was observed between the treatment arms in the level of fasting blood glucose (P = 0.055) and liver enzymes, such as alkaline phosphatase (P = 0.109), serum glutamic-oxaloacetic transaminase (P = 0.366), and serum glutamic pyruvic transaminase (P = 0.436). The effect of berberine on body weight was also nonsignificant (P = 0.494) and even smaller than that of liver enzymes, with a mean difference of 1.8 kg (P = 0.304) in body weight.
Conclusion: Berberine was not associated with a significant decrease in lipid profile, fasting blood glucose, or liver enzymes among patients with NAFLD.
Roya Alipour, Naheed Aryaeian, Ghazaleh Hajiluian, Mansoure Soleimani, Mahmood Barati,
Volume 37, Issue 1 (2-2023)
Abstract
Background: According to the worldwide increasing prevalence of non-alcoholic fatty liver disease (NAFLD), the present study aimed to investigate the mechanism effects of saffron consumption on preventing NAFLD in a rat model.
Methods: In an experimental study, 12 rats were randomly divided into 2 groups to be evaluated in the prevention phase for 7 weeks. In the prevention phase, the animals were randomly assigned to either fed HFHS + 250 mg/kg saffron (S) or fed with HFHS. Afterward, parts of the liver were excised for histopathologic examination. Plasma concentrations of ALT, AST, GGT, ALP, serum lipids, insulin concentrations, plasma glucose, hs-CRP, and TAC were measured. Moreover, Also, the gene expression of 6 target genes was evaluated, including FAS, ACC1, CPT1 ،PPARα ،DGAT2, and SREBP 1-c at the beginning and end of the study. Also, the differences among groups were evaluated by the Mann-Whitney test for non-normal data and the independent t test for normal data.
Results: The prevention phase groups have a significant elevation in body weight (P = 0.034) and food intake (P = 0.001) of the HFHS group versus HFHS + 250 mg/kg S group. Also, there was a significant difference between groups 1 and 2 for ALT (P = 0.011) and AST (P = 0.010), and TG (P = 0.040). The HFHS group had higher plasma levels of FBS (P = 0.001), insulin (P = 0.035), HOMA-IR (P = 0.032), and lower TAC (P = 0.041) versus the HFHS+ S group. Also, the difference between HFHS + 250 mg/kg S and HFHS for PPARα gene expression was significant (P = 0.030).
Conclusion: The present study showed that consumption of saffron could prevent developing NAFLD in rats at least partially through modulation in gene expression of PPARα.
